메뉴 건너뛰기




Volumn 5, Issue , 2013, Pages 185-192

Cytochrome P450 3A4*22, PPAR-α, and ARNT polymorphisms and clopidogrel response

Author keywords

Clopidogrel; CYP450; Pharmacogenetics; Platelet aggregation

Indexed keywords

ADENOSINE DIPHOSPHATE; CLOPIDOGREL; CYTOCHROME P450 3A4; HYPOXIA INDUCIBLE FACTOR 1BETA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

EID: 84890362511     PISSN: None     EISSN: 11791438     Source Type: Journal    
DOI: 10.2147/CPAA.S53151     Document Type: Article
Times cited : (19)

References (33)
  • 1
    • 73149119363 scopus 로고    scopus 로고
    • Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite
    • Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos. 2010; 38(1): 92-99.
    • (2010) Drug Metab Dispos , vol.38 , Issue.1 , pp. 92-99
    • Kazui, M.1    Nishiya, Y.2    Ishizuka, T.3
  • 2
    • 79960613122 scopus 로고    scopus 로고
    • Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-452C19 (CYP2C19) genotype and clopidogrel therapy
    • Scott SA, Sangkuhl K, Gardner EE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-452C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther. 2011; 90(2): 328-332.
    • (2011) Clin Pharmacol Ther , vol.90 , Issue.2 , pp. 328-332
    • Scott, S.A.1    Sangkuhl, K.2    Gardner, E.E.3
  • 3
    • 84871919080 scopus 로고    scopus 로고
    • The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response
    • Lewis JP, Horenstein RB, Ryan K, et al. The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. Pharmacogenet Genomics. 2013; 23(1): 1-8.
    • (2013) Pharmacogenet Genomics , vol.23 , Issue.1 , pp. 1-8
    • Lewis, J.P.1    Horenstein, R.B.2    Ryan, K.3
  • 4
    • 78650517232 scopus 로고    scopus 로고
    • Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: Randomized, placebo-controlled, crossover comparison studies
    • Angiolillo DJ, Gibson CM, Cheng S, et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011; 89(1): 65-74.
    • (2011) Clin Pharmacol Ther , vol.89 , Issue.1 , pp. 65-74
    • Angiolillo, D.J.1    Gibson, C.M.2    Cheng, S.3
  • 6
    • 47649111604 scopus 로고    scopus 로고
    • The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects
    • Umemura K, Furuta T, Kondo K. The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects. J Thromb Haemost. 2008; 6(8): 1439-1441.
    • (2008) J Thromb Haemost , vol.6 , Issue.8 , pp. 1439-1441
    • Umemura, K.1    Furuta, T.2    Kondo, K.3
  • 7
    • 84863294612 scopus 로고    scopus 로고
    • Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response
    • Kreutz RP, Nystrom P, Kreutz Y, et al. Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response. Clin Pharmacol. 2012; 4: 13-20.
    • (2012) Clin Pharmacol , vol.4 , pp. 13-20
    • Kreutz, R.P.1    Nystrom, P.2    Kreutz, Y.3
  • 8
    • 69249219296 scopus 로고    scopus 로고
    • Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clincal efficacy of clopidogrel
    • Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clincal efficacy of clopidogrel. JAMA. 2009; 302(8): 849-857.
    • (2009) JAMA , vol.302 , Issue.8 , pp. 849-857
    • Shuldiner, A.R.1    O'Connell, J.R.2    Bliden, K.P.3
  • 9
    • 1642453779 scopus 로고    scopus 로고
    • Contribution of hepatic cytochrome P450 3 A4 metabolic activity to the phenomenon of clopidogrel resistance
    • Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome P450 3 A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation. 2004; 109(2): 166-171.
    • (2004) Circulation , vol.109 , Issue.2 , pp. 166-171
    • Lau, W.C.1    Gurbel, P.A.2    Watkins, P.B.3
  • 10
    • 78951472564 scopus 로고    scopus 로고
    • The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: Increased platelet inhibition by enhancement of CYP3A4 metabolic activity
    • Lau WC, Welch TD, Shields T, Rubenfire M, Tantry US, Gurbel PA. The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity. J Cardiovasc Pharmacol. 2011; 57(1): 86-93.
    • (2011) J Cardiovasc Pharmacol , vol.57 , Issue.1 , pp. 86-93
    • Lau, W.C.1    Welch, T.D.2    Shields, T.3    Rubenfire, M.4    Tantry, U.S.5    Gurbel, P.A.6
  • 11
    • 58749094444 scopus 로고    scopus 로고
    • Cytochrome p-450 polymorphisms and response to clopidogrel
    • Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009; 360(4): 354-362.
    • (2009) N Engl J Med , vol.360 , Issue.4 , pp. 354-362
    • Mega, J.L.1    Close, S.L.2    Wiviott, S.D.3
  • 12
    • 84874550138 scopus 로고    scopus 로고
    • Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function
    • Frelinger AL 3rd, Bhatt DL, Lee RD, et al. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol. 2013; 61(8): 872-879.
    • (2013) J Am Coll Cardiol , vol.61 , Issue.8 , pp. 872-879
    • Frelinger III, A.L.1    Bhatt, D.L.2    Lee, R.D.3
  • 13
    • 0036890399 scopus 로고    scopus 로고
    • The cytochrome P450 superfamily: Biochemistry, evolution and drug metabolism in humans
    • Danielson PB. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr Drug Metab. 2002; 3(6): 561-597.
    • (2002) Curr Drug Metab , vol.3 , Issue.6 , pp. 561-597
    • Danielson, P.B.1
  • 14
    • 84871450636 scopus 로고    scopus 로고
    • CYP3A4*22: Promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy
    • Elens L, van Gelder T, Hesselink DA, Haufroid V, van Schaik RH. CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. Pharmacogenomics. 2013; 14(1): 47-62.
    • (2013) Pharmacogenomics , vol.14 , Issue.1 , pp. 47-62
    • Elens, L.1    van Gelder, T.2    Hesselink, D.A.3    Haufroid, V.4    van Schaik, R.H.5
  • 15
    • 84861342919 scopus 로고    scopus 로고
    • PPARA: A novel genetic determinant of CYP3A4 in vitro and in vivo
    • Klein K, Thomas M, Winter S, et al. PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo. Clin Pharmacol Ther. 2012; 91(6): 1044-1052.
    • (2012) Clin Pharmacol Ther , vol.91 , Issue.6 , pp. 1044-1052
    • Klein, K.1    Thomas, M.2    Winter, S.3
  • 16
    • 79960633918 scopus 로고    scopus 로고
    • Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs
    • Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 2011; 11(4): 274-286.
    • (2011) Pharmacogenomics J , vol.11 , Issue.4 , pp. 274-286
    • Wang, D.1    Guo, Y.2    Wrighton, S.A.3    Cooke, G.E.4    Sadee, W.5
  • 17
    • 0000783041 scopus 로고    scopus 로고
    • Evaluation of the genetic component of variability in CYP3A4 activity: A repeated drug administration method
    • Ozdemir V, Kalow W, Tang BK, et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics. 2000; 10(5): 373-388.
    • (2000) Pharmacogenetics , vol.10 , Issue.5 , pp. 373-388
    • Ozdemir, V.1    Kalow, W.2    Tang, B.K.3
  • 18
    • 80054924410 scopus 로고    scopus 로고
    • A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients
    • Elens L, Bouamar R, Hesselink DA, et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem. 2011; 57(11): 1574-1583.
    • (2011) Clin Chem , vol.57 , Issue.11 , pp. 1574-1583
    • Elens, L.1    Bouamar, R.2    Hesselink, D.A.3
  • 19
    • 81055140354 scopus 로고    scopus 로고
    • Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study
    • Elens L, Becker ML, Haufroid V, et al. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. Pharmacogenet Genomics. 2011; 21(12): 861-866.
    • (2011) Pharmacogenet Genomics , vol.21 , Issue.12 , pp. 861-866
    • Elens, L.1    Becker, M.L.2    Haufroid, V.3
  • 20
    • 84859900517 scopus 로고    scopus 로고
    • The new CYP3A4 intron 6 C. T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients
    • Elens L, Bouamar R, Hesselink DA, Haufroid V, van Gelder T, van Schaik RH. The new CYP3A4 intron 6 C. T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients. Pharmacogenet Genomics. 2012; 22(5): 373-380.
    • (2012) Pharmacogenet Genomics , vol.22 , Issue.5 , pp. 373-380
    • Elens, L.1    Bouamar, R.2    Hesselink, D.A.3    Haufroid, V.4    van Gelder, T.5    van Schaik, R.H.6
  • 21
    • 38349168418 scopus 로고    scopus 로고
    • A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry
    • Jakubowski JA, Payne CD, Li YG, et al. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry. Thromb Haemost. 2008; 99(1): 215-222.
    • (2008) Thromb Haemost , vol.99 , Issue.1 , pp. 215-222
    • Jakubowski, J.A.1    Payne, C.D.2    Li, Y.G.3
  • 22
    • 73949112820 scopus 로고    scopus 로고
    • Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: The ONSET/OFFSET study
    • Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009; 120(25): 2577-2585.
    • (2009) Circulation , vol.120 , Issue.25 , pp. 2577-2585
    • Gurbel, P.A.1    Bliden, K.P.2    Butler, K.3
  • 23
    • 35848934339 scopus 로고    scopus 로고
    • Inflammatory changes during the 'common cold' are associated with platelet activation and increased reactivity of platelets to agonists
    • Kreutz RP, Tantry US, Bliden KP, Gurbel PA. Inflammatory changes during the 'common cold' are associated with platelet activation and increased reactivity of platelets to agonists. Blood Coagul Fibrinolysis. 2007; 18(8): 713-718.
    • (2007) Blood Coagul Fibrinolysis , vol.18 , Issue.8 , pp. 713-718
    • Kreutz, R.P.1    Tantry, U.S.2    Bliden, K.P.3    Gurbel, P.A.4
  • 24
    • 79953114829 scopus 로고    scopus 로고
    • Morbid obesity and metabolic syndrome in Ossabaw miniature swine are associated with increased platelet reactivity
    • Kreutz RP, Alloosh M, Mansour K, et al. Morbid obesity and metabolic syndrome in Ossabaw miniature swine are associated with increased platelet reactivity. Diabetes Metab Syndr Obes. 2011; 4: 99-105.
    • (2011) Diabetes Metab Syndr Obes , vol.4 , pp. 99-105
    • Kreutz, R.P.1    Alloosh, M.2    Mansour, K.3
  • 25
    • 84864409943 scopus 로고    scopus 로고
    • Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependent on clopidogrel response
    • Kreutz RP, Breall JA, Kreutz Y, et al. Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependent on clopidogrel response. Thromb Res. 2012; 130(2): 198-202.
    • (2012) Thromb Res , vol.130 , Issue.2 , pp. 198-202
    • Kreutz, R.P.1    Breall, J.A.2    Kreutz, Y.3
  • 26
    • 27444434164 scopus 로고    scopus 로고
    • Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation
    • Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol. 2005; 46(9): 1705-1709.
    • (2005) J Am Coll Cardiol , vol.46 , Issue.9 , pp. 1705-1709
    • Tantry, U.S.1    Bliden, K.P.2    Gurbel, P.A.3
  • 27
    • 84877780144 scopus 로고    scopus 로고
    • The CYP3A4 intron 6 C. T polymorphism (CYP3A4*22) is associated with reduced CYP3A4 protein level and function in human liver microsomes
    • Okubo M, Murayama N, Shimizu M, Shimada T, Guengerich FP, Yamazaki H. The CYP3A4 intron 6 C. T polymorphism (CYP3A4*22) is associated with reduced CYP3A4 protein level and function in human liver microsomes. J Toxicol Sci. 2013; 38(3): 349-354.
    • (2013) J Toxicol Sci , vol.38 , Issue.3 , pp. 349-354
    • Okubo, M.1    Murayama, N.2    Shimizu, M.3    Shimada, T.4    Guengerich, F.P.5    Yamazaki, H.6
  • 28
    • 57149084688 scopus 로고    scopus 로고
    • Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects
    • Farid NA, Small DS, Payne CD, et al. Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects. Pharmacotherapy. 2008; 28(12): 1483-1494.
    • (2008) Pharmacotherapy , vol.28 , Issue.12 , pp. 1483-1494
    • Farid, N.A.1    Small, D.S.2    Payne, C.D.3
  • 29
    • 58149466606 scopus 로고    scopus 로고
    • PPARs mediate lipid signaling in inflammation and cancer
    • Michalik L, Wahli W. PPARs mediate lipid signaling in inflammation and cancer. PPAR Res. 2008; 2008: 134059.
    • (2008) PPAR Res , vol.2008 , pp. 134059
    • Michalik, L.1    Wahli, W.2
  • 30
    • 69449086702 scopus 로고    scopus 로고
    • Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human
    • Rakhshandehroo M, Hooiveld G, Müller M, Kersten S. Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human. PLoS One. 2009; 4(8): e6796.
    • (2009) PLoS One , vol.4 , Issue.8
    • Rakhshandehroo, M.1    Hooiveld, G.2    Müller, M.3    Kersten, S.4
  • 33
    • 82955189275 scopus 로고    scopus 로고
    • A point-of-care platelet function assay and C-reactive protein for prediction of major cardiovascular events after drug-eluting stent implantation
    • Park DW, Lee SW, Yun SC, et al. A point-of-care platelet function assay and C-reactive protein for prediction of major cardiovascular events after drug-eluting stent implantation. J Am Coll Cardiol. 2011; 58(25): 2630-2639.
    • (2011) J Am Coll Cardiol , vol.58 , Issue.25 , pp. 2630-2639
    • Park, D.W.1    Lee, S.W.2    Yun, S.C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.